Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)

Affiliations

• ¹ Steno Diabetes Center Copenhagen, Herlev, Denmark.
• ² Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
• ³ Swiss Eye Institute, Rotkreuz, and Berner Augenklinik, Bern, Switzerland.
• ⁴ Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland.
• ⁵ Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
• ⁶ Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland.
• ⁷ Nakakinen Clinic, Naka, Japan.
• ⁸ University of Michigan School of Medicine, Ann Arbor, Michigan.
• ⁹ Joslin Diabetes Center and Harvard Medical School, Boston, Massachusetts.
• ¹⁰ Hypertension Unit and Cardiorenal Translational Laboratory, Madrid, Spain.
• ¹¹ Department of Endocrinology and Metabolism, DrumTower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
• ¹² Bayer AG, Wuppertal, Germany.
• ¹³ Bayer Consumer Care AG, Basel, Switzerland.
• ¹⁴ Bayer AG, Berlin, Germany.
• ¹⁵ American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, Illinois.